Vasomotor symptoms (VMS) and endothelial function: A randomised placebo-controlled trial of oral micronised Progesterone (Prometrium).

Trial Profile

Vasomotor symptoms (VMS) and endothelial function: A randomised placebo-controlled trial of oral micronised Progesterone (Prometrium).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2014

At a glance

  • Drugs Progesterone (Primary)
  • Indications Menopausal syndrome; Vasomotor symptoms
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms VMS Progesterone
  • Most Recent Events

    • 21 Sep 2011 Planned end date changed from 31 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 May 2009 Lead trial centre added and actual start date changed from Sep 2005 to Jan 2003 as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top